Brief: Aerovate Therapeutics Presents Phase 1 Data For Pulmonary Arterial Hypertension Treatment
16/05/2022 22:24
May 16 (Reuters) - Aerovate Therapeutics Inc AVTE.O :
* AEROVATE THERAPEUTICS PRESENTS PHASE 1 DATA FOR AV-101, A
NOVEL
DRY POWDER INHALED FORMULATION OF IMATINIB BEING DEVELOPED FOR
THE TREATMENT OF PATIENTS WITH PULMONARY ARTERIAL HYPERTENSION
(PAH)
* AEROVATE THERAPEUTICS INC - PHASE 1 RESULTS SHOW THAT
AV-101
DELIVERED BY DRY POWDER INHALATION WAS GENERALLY WELL TOLERATED
* AEROVATE THERAPEUTICS - RESULTS SHOW AV-101 SIGNIFICANTLY
REDUCED SYSTEMIC EXPOSURE COMPARED WITH ORAL IMATINIB IN HEALTHY
ADULT PARTICIPANTS
Source text for Eikon: ID:nGNX9C0pPZ
Further company coverage: AVTE.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Jade Biosciences
See all newsBrief: Jade Biosciences Announces Preclinical Data Characterizing Jade301, A Potentially Best-In-Class, Half-Life-Extended Anti-Ifn-Β Monoclonal Antibody In Development For Dermatomyositis, At Eadv 2026
U.S. RESEARCH ROUNDUP-Cardinal Health, Lumentum Holdings, Public Storage
Jade Biosciences Inc reports results for the quarter ended June 30 - Earnings Summary
Jade Biosciences Q2 net loss widens as costs rise
Brief: Jade Biosciences, Inc Q2 Cash & Investments USD 461.2 Million